Follicular Lymphoma
📧 Sign up to get email alerts when something new happens for Follicular Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-01-10Clinical Trial Update: Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT) [Phase 3]
Phase 3 trial update for Follicular Lymphoma evaluating IV/SC Rituximab therapy (FLIRT) has completed.
-
CLINICAL_TRIALS trial_result · 2023-01-10Clinical Trial Update: Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas [Phase 2]
Phase 2 clinical trial evaluating the atezolizumab-venetoclax-obinutuzumab combination in relapse/refractory lymphomas has completed enrollm…
-
CLINICAL_TRIALS trial_result · 2022-12-30Clinical Trial Update: Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases [Phase 2]
A Phase 2 pembrolizumab trial in untreated B-cell non-Hodgkin lymphoproliferative diseases has been terminated; results have been posted.
-
FDA approval · 2022-12-22FDA Approved: LUNSUMIO — Original Application (Genentech, Inc.)
The FDA approved Lunsumio (mosunetuzumab) from Genentech in an original application for adults with relapsed or refractory follicular lympho…
-
FDA approval · 2022-12-07FDA Approved: VIVIMUSTA — Original Application (Azurity Pharmaceuticals, Inc.)
FDA approved VIVIMUSTA (bendamustine hydrochloride) from Azurity Pharmaceuticals under Original Application NDA212209.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-12-07FDA Approved: BENDAMUSTINE HYDROCHLORIDE — Original Application (Apotex Corp)
FDA approved bendamustine hydrochloride via Apotex Corp's original application, indicating the approval of a Bendamustine HCl product.
-
CLINICAL_TRIALS trial_result · 2022-11-18Clinical Trial Update: Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma [Phase 3]
Phase 3 trial comparing radiotherapy alone versus radiotherapy plus chemotherapy in early-stage follicular lymphoma completed.
-
CLINICAL_TRIALS trial_result · 2022-11-17Clinical Trial Update: Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma [Phase 1, Phase 2]
A completed Phase 1/2 clinical trial evaluated lenalidomide and rituximab in combination with chemotherapy for newly diagnosed diffuse large…
-
CLINICAL_TRIALS trial_result · 2022-11-14Clinical Trial Update: A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 study of polatuzumab vedotin in combination with rituximab or obinutuzumab plus bendamustine in relapsed/refractory follicular lym…
-
FDA approval · 2022-09-06FDA Approved: LENALIDOMIDE — Original Application (EXELAN PHARMACEUTICALS INC.)
The FDA approved Exelan Pharmaceuticals Inc.'s original application for lenalidomide, granting approval of a generic version of the cancer d…
-
FDA approval · 2022-08-31FDA Approved: LENALIDOMIDE — Original Application (Alvogen, Inc.)
FDA approved the original application for Lenalidomide from Alvogen, Inc., enabling a generic version of lenalidomide to enter the market.
-
FDA approval · 2022-08-30FDA Approved: LENALIDOMIDE — Original Application (Mylan Pharmaceuticals Inc.)
FDA approved lenalidomide as an original application for Mylan Pharmaceuticals Inc., establishing a generic version of lenalidomide.
-
CLINICAL_TRIALS trial_result · 2022-07-22Clinical Trial Update: Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma [Phase 2]
Phase 2 trial evaluating the efficacy and safety of Kymriah (tisagenlecleucel) in adults with refractory or relapsed follicular lymphoma; re…
-
CLINICAL_TRIALS trial_result · 2022-07-21Clinical Trial Update: Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma [Phase 2, Phase 3]
Phase 2/3 trial assessing ublituximab + umbralisib with or without bendamustine, and umbralisib alone, in previously treated non-Hodgkin lym…
-
CLINICAL_TRIALS trial_result · 2022-07-18Clinical Trial Update: Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy [Phase 2]
Phase II trial evaluating frontline triplet therapy with venetoclax, obinutuzumab, and bendamustine in patients with high tumor burden folli…
-
CLINICAL_TRIALS withdrawal · 2022-07-18Clinical Trial Update: To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302) [Phase 3]
A Phase 3 clinical trial evaluating parsaclisib with rituximab or obinutuzumab in relapsed/refractory follicular lymphoma and marginal zone …
-
FDA approval · 2022-07-06FDA Approved: ZYDELIG — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for ZYDELIG (idelalisib) submitted by Gilead Sciences, Inc. The specific changes to the product'…
-
FDA label_change · 2022-06-30FDA Approved: LENALIDOMIDE — Supplemental Application (Dr. Reddy's Laboratories Inc.)
FDA approved a supplemental application for lenalidomide submitted by Dr. Reddy's Laboratories Inc., resulting in updated labeling for the d…
-
CLINICAL_TRIALS trial_result · 2022-06-21Clinical Trial Update: "MIRO" Molecularly Oriented Immuno-radio-therapy [Phase 2]
Phase 2 trial update for MIRO molecularly oriented immuno-radio-therapy in follicular lymphoma patients has completed recruitment.
-
FDA approval · 2022-06-03FDA Approved: RIABNI — Supplemental Application (Amgen, Inc)
FDA approved a supplemental application for RIABNI (rituximab-arrx) from Amgen. The action updates RIABNI’s labeling to reflect its approved…
-
CLINICAL_TRIALS trial_result · 2022-05-06Clinical Trial Update: ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies [Phase 1, Phase 2]
Phase 1/2 trial of acalabrutinib (ACP-196) in combination with pembrolizumab in hematologic malignancies has completed with results posted i…
-
CLINICAL_TRIALS trial_result · 2022-04-22Clinical Trial Update: Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma [Phase 2]
Phase 2 trial evaluating R-FND chemotherapy plus Zevalin for high-risk follicular lymphoma has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2022-04-05Clinical Trial Update: Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL [Phase 1, Phase 2]
Phase 1/2a dose-escalation study in CLL/SLL and various NHL subtypes completed with results posted.
-
FDA approval · 2022-03-10FDA Approved: ZYDELIG — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for ZYDELIG (idelalisib) from Gilead Sciences, Inc. The action updates the labeling for the drug…
-
CLINICAL_TRIALS trial_result · 2022-02-10Clinical Trial Update: A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma [Phase 2]
Phase 2 study of INCB050465 in relapsed or refractory follicular lymphoma has completed, with results posted. The sponsor is Incyte Corporat…